In this study, we showed that a small molecule STING agonist efficiently reprogramed TAMs from a pro-tumorigenic to an anti-tumorigenic state characterized by induction of type I IFN responses and expression of the co-stimulatory molecule CD86, which may stimulate T cell cross-priming and trigger a robust adaptive anti-tumor immunity39. The gene discussed is CD86; the disease is neoplasm.